Bcl-6 protein expression, and not the germinal centre immunophenotype, predicts favourable prognosis in a series of primary nodal diffuse large B-cell lymphomas: A single centre experience

References

• De Paepe P, De Wolf-Peeters C. Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia 2007; 21: 37–43
   PubMed Web of Science ®Google Scholar
• Alizadeh A A, Eisen M B, Davis R E, Ma C, Lossos I S, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan W C, Connors J M, Campo E, Fisher R I, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947
   PubMed Web of Science ®Google Scholar
• Barrans S L, Carter I, Owen R G, Davies F E, Patmore R D, Haynes A P, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99: 1136–1143
   PubMed Web of Science ®Google Scholar
• Biasoli I, Morais J C, Scheliga A, Milito C B, Romano S, Land M, et al. CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses. Histopathology 2005; 46: 328–333
   PubMed Web of Science ®Google Scholar
• Chang C C, McClintock S, Cleveland R P, Trzpuc T, Vesole D H, Logan B, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004; 28: 464–470
   PubMed Web of Science ®Google Scholar
• McCluggage W G, Catherwood M, Alexander H D, McBride H A, Smith M E, Morris T C. Immunohistochemical expression of CD10 and t(14;18) chromosomal translocation may be indicators of follicle centre cell origin in nodal diffuse large B-cell lymphoma. Histopathology 2002; 41: 414–420
   PubMed Web of Science ®Google Scholar
• Hans C P, Weisenburger D D, Greiner T C, Gascoyne R D, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282
   PubMed Web of Science ®Google Scholar
• Muris J J, Meijer C J, Vos W, van Krieken J H, Jiwa N M, Ossenkoppele G J, Oudejans J J. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 2006; 208: 714–723
   PubMed Web of Science ®Google Scholar
• Berglund M, Thunberg U, Amini R M, Book M, Roos G, Erlanson M, et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 2005; 18: 1113–1120
   PubMed Web of Science ®Google Scholar
• Sjö L D, CB Puolsen, Hansen M, Møller M B, Ralfkiaer E. Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. Eur J Haematol 2007; 501–507
   PubMed Web of Science ®Google Scholar
• Nyman H, Adde M, Karjalainen-lindsberg M L, Taskinen M, Berglund M, Amini R M, et al. Prognostic impact of immunohistochemically defined germinal centre immunophenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109: 4930–4935
   PubMed Web of Science ®Google Scholar
• Uccella S, Cerutti R, Vigetti D, Furlan D, Oldrini R, Carnevali I, et al. Histidine decarboxylase, DOPA decarboxylase, and vesicular monoamine transporter 2 expression in neuroendocrine tumors: immunohistochemical study and gene expression analysis. J Histochem Cytochem 2006; 54: 863–875
   PubMed Web of Science ®Google Scholar
• BD Cheson, B Pfistner, ME Juweid, RD Gascoyne, L Specht, Horning S J, et al. The International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586
   PubMed Web of Science ®Google Scholar
• Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martínez A, Bosch F, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78–84
   PubMed Web of Science ®Google Scholar
• Iqbal J, Neppalli V T, Wright G, Dave B J, Horsman D E, Rosenwald A, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 961–968
   PubMed Web of Science ®Google Scholar
• Ohshima K, Kawasaki C, Muta H, Muta K, Deyev V, Haraoka S, et al. CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 2001; 39: 156–162
   PubMed Web of Science ®Google Scholar
• Sohn S K, Jung J T, Kim D H, Kim J G, Kwak E K, Park T, et al. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma. Am J Hematol 2003; 73: 101–107
   PubMed Web of Science ®Google Scholar
• Uherova P, Ross C W, Schnitzer B, Singleton T P, Finn W G. The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma. Am J Clin Pathol 2001; 115: 582–588
   PubMed Web of Science ®Google Scholar
• Xu Y, McKenna R W, Molberg K H, Kroft S H. Clinicopathologic analysis of CD10+ and CD10− diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2. Am J Clin Pathol 2001; 116: 183–190
   PubMed Web of Science ®Google Scholar
• Lossos I S, Jones C D, Warnke R, Natkunam Y, Kaizer H, Zehnder J L, et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001; 98: 945–951
   PubMed Web of Science ®Google Scholar
• Lossos I S, Czerwinski D K, Alizadeh A A, Wechser M A, Tibshirani R, Botstein D, Levy R. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350: 1828–1837
   PubMed Web of Science ®Google Scholar
• Winter J N, Weller E A, Horning S J, Krajewska M, Variakojis D, Habermann T M, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006; 107: 4207–4213
   PubMed Web of Science ®Google Scholar
• Fabiani B, Delmer A, Lepage E, Guettier C, Petrella T, Brière J, et al. CD10 expression in diffuse large B-cell lymphomas does not influence survival. Virchows Arch 2004; 445: 545–551
   PubMed Web of Science ®Google Scholar
• Mounier N, Briere J, Gisselbrecht C, Emile J F, Lederlin P, Sebban C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279–4284
   PubMed Web of Science ®Google Scholar
• Habermann T M, Weller E A, Morrison V A, Gascoyne R D, Cassileth P A, Cohn J B, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121–3127
   PubMed Web of Science ®Google Scholar
• W Hiddemann, M Kneba, M Dreyling, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725–3732
   PubMed Web of Science ®Google Scholar